| Dabrafenib studied in …STUDIED_INderived123 of 123show fewer |
|---|
| → studied in | NCT06475989Phase 3 · recruiting Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · 123 trials list this drug (36 active) | — | — | Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03340506Phase 4 · recruiting Dabrafenib and/or Trametinib Rollover Study · 123 trials list this drug (36 active) | — | — | Solid Neoplasm,Melanoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04940052Phase 3 · active not recruiting Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer · 123 trials list this drug (36 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544111Phase 2 · active not recruiting PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · 123 trials list this drug (36 active) | — | — | Thyroid Gland Follicular Carcinoma,Malignant Thyroid Gland Neoplasm,Thyroid Gland Oncocytic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02196181Phase 2 · active not recruiting Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread · 123 trials list this drug (36 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03149029Phase 2 · active not recruiting Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04201457Phase 1/Phase 2 · active not recruiting A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration · 123 trials list this drug (36 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07110246Phase 2 · recruiting Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · 123 trials list this drug (36 active) | — | — | Low Grade Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04557956Phase 1/Phase 2 · active not recruiting Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02224781Phase 3 · active not recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 123 trials list this drug (36 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03975829Phase 4 · active not recruiting Pediatric Long-Term Follow-up and Rollover Study · 123 trials list this drug (36 active) | — | — | Anaplastic Astrocytoma,Anaplastic Ganglioglioma,Anaplastic Oligodendroglioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02858921Phase 2 · active not recruiting Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07440290Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. · 123 trials list this drug (36 active) | — | — | Neoplasm by Site,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01989585Phase 1/Phase 2 · active not recruiting Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma · 123 trials list this drug (36 active) | — | — | Malignant Solid Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04675710Phase 2 · active not recruiting Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer · 123 trials list this drug (36 active) | — | — | Thyroid Gland Anaplastic Carcinoma,Thyroid Gland Anaplastic Carcinoma, Squamous Cell Carcinoma Pattern | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02231775Phase 2 · active not recruiting Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation · 123 trials list this drug (36 active) | — | — | Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04527549Phase 2 · terminated Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03091257Phase 1 · active not recruiting A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma · 123 trials list this drug (36 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03919071Phase 2 · active not recruiting Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma · 123 trials list this drug (36 active) | — | — | Anaplastic Astrocytoma,Anaplastic Ganglioglioma,Anaplastic Pleomorphic Xanthoastrocytoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04116541Phase 2 · recruiting A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. · 123 trials list this drug (36 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04238624Phase 2 · active not recruiting Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer · 123 trials list this drug (36 active) | — | — | Thyroid Gland Neoplasm,Malignant Thyroid Gland Neoplasm,Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01972347Phase 2 · completed Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439292Phase 2 · active not recruiting Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) · 123 trials list this drug (36 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02910700Phase 2 · active not recruiting Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01947023Phase 1 · active not recruiting Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery · 123 trials list this drug (36 active) | — | — | Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01682083Phase 3 · completed Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03975231Phase 1 · recruiting Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer · 123 trials list this drug (36 active) | — | — | Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07506109Phase 2 · recruiting A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer · 123 trials list this drug (36 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03244956Phase 2 · completed Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer · 123 trials list this drug (36 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04666272active not recruiting Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04903119Phase 1 · recruiting Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04452877Phase 2 · completed A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC · 123 trials list this drug (36 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04294160Phase 1 · terminated A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer · 123 trials list this drug (36 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04489433no longer available Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04961619completed Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02967692Phase 3 · terminated A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04418167Phase 1 · suspended JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations · 123 trials list this drug (36 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01723202Phase 2 · completed Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer · 123 trials list this drug (36 active) | — | — | Thyroid Gland Follicular Carcinoma,Thyroid Gland Neoplasm,Malignant Thyroid Gland Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05388877Phase 1 · terminated E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07010393Phase 4 · not yet recruiting Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · 123 trials list this drug (36 active) | — | — | Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03551626Phase 3 · completed Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06119789Phase 2 · recruiting Precision Cancer Therapy in Rare Cancers · 123 trials list this drug (36 active) | — | — | Rare Childhood Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05260684completed Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03026517Phase 1 · completed Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01902173Phase 1/Phase 2 · completed Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer · 123 trials list this drug (36 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm,Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06739395Phase 2 · recruiting Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion · 123 trials list this drug (36 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04507919no longer available Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer · 123 trials list this drug (36 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544202no longer available Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04310397Phase 2 · terminated Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma · 123 trials list this drug (36 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06653517Phase 2 · recruiting Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma · 123 trials list this drug (36 active) | — | — | Ameloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02097225Phase 1 · terminated Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · 123 trials list this drug (36 active) | — | — | Solid Neoplasm,Malignant Solid Neoplasm,Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532149recruiting ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · 123 trials list this drug (36 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03455764Phase 1/Phase 2 · completed MCS110 With BRAF/MEK Inhibition in Patients With Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05159245Phase 2 · recruiting The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs · 123 trials list this drug (36 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739566Phase 2 · withdrawn Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer · 123 trials list this drug (36 active) | — | — | Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 123 trials list this drug (36 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06264778Phase 3 · unknown Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma · 123 trials list this drug (36 active) | — | — | Ameloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02367859Phase 2 · completed Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma · 123 trials list this drug (36 active) | — | — | Ameloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 123 trials list this drug (36 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02684058Phase 2 · completed Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors · 123 trials list this drug (36 active) | — | — | Anaplastic Astrocytoma,Anaplastic Ganglioglioma,Anaplastic Oligodendroglioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05876806Phase 2 · unknown Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02143050Phase 1/Phase 2 · withdrawn Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05182931Phase 2 · unknown A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) · 123 trials list this drug (36 active) | — | — | Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04059224Phase 2 · completed TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03272464Phase 1 · terminated INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05299580Phase 2 · withdrawn "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02034110Phase 2 · completed Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03563729Phase 2 · recruiting Melanoma Metastasized to the Brain and Steroids · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04801966NA · terminated Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02052193Phase 2 · terminated Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02130466Phase 1/Phase 2 · completed A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) · 123 trials list this drug (36 active) | — | — | Solid Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03668431Phase 2 · unknown Dabrafenib + Trametinib + PDR001 In Colorectal Cancer · 123 trials list this drug (36 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05171374unknown pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01336634Phase 2 · completed Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01940809Phase 1 · terminated Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery · 123 trials list this drug (36 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03239015Phase 2 · unknown Efficacy and Safety of Precision Therapy in Refractory Tumor · 123 trials list this drug (36 active) | — | — | Neoplasm,Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02083354Phase 2 · completed Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01677741Phase 1/Phase 2 · completed A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects · 123 trials list this drug (36 active) | — | — | Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01750918Phase 1/Phase 2 · completed BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02974803Phase 2 · terminated Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases · 123 trials list this drug (36 active) | — | — | Melanoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02124772Phase 1/Phase 2 · completed Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03754179Phase 1/Phase 2 · unknown Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02110355Phase 1 · completed A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma · 123 trials list this drug (36 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01597908Phase 3 · completed Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01584648Phase 3 · completed A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03352947Phase 2 · completed Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03972046Phase 2 · withdrawn Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02410863Phase 2 · terminated Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03088176Phase 1 · unknown Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01682213Phase 2 · completed Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03391050Phase 1/Phase 2 · terminated A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01072175Phase 2 · completed Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02039947Phase 2 · completed Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain · 123 trials list this drug (36 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02027961Phase 1 · completed Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01231594Phase 1 · completed A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01713972Phase 1 · completed Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors · 123 trials list this drug (36 active) | — | — | Adult Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314143Phase 2 · terminated Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02447939Phase 1 · withdrawn Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01978236Phase 2 · terminated Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites · 123 trials list this drug (36 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01907802Phase 1 · terminated Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction · 123 trials list this drug (36 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02672358Phase 2 · withdrawn Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC · 123 trials list this drug (36 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03553329completed Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK · 123 trials list this drug (36 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02915666Phase 1 · withdrawn A Clinical Trial of Patients With Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01721603Phase 2 · terminated Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01767454Phase 1 · completed Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma · 123 trials list this drug (36 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00880321Phase 1 · completed A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01262963Phase 1 · completed An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01340833Phase 1 · completed Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01340846Phase 1 · completed A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01582997Phase 1 · completed A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01738451Phase 1 · completed A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01227889Phase 3 · completed A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01153763Phase 2 · completed A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02625337Phase 2 · unknown Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02416232no longer available Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01928940Phase 2 · completed Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) · 123 trials list this drug (36 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02082665Phase 1 · completed Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam · 123 trials list this drug (36 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01701037Phase 2 · terminated Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01534897NA · completed Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 · 123 trials list this drug (36 active) | — | — | Thyroid Gland Papillary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01619774Phase 2 · completed An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02357732Phase 1 · withdrawn Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib · 123 trials list this drug (36 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01266967Phase 2 · completed A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain · 123 trials list this drug (36 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |